HSGX News and Press, Histogenics Corporation From 02/20/19

HENDERSON, NV / ACCESSWIRE / February 20, 2019 / Biotech may have had a hard 2018, but the sector is making up for lost time at the start of this year. This may be just getting started as many fund managers are underweight in the industry and may have to chase this run. One more under the ra...

SOMERVILLE, Mass., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Danforth Advisors, LLC, a consulting firm providing operational accounting and finance support, together with CFO services, for private and public life science companies, today announced the appointment of Jonathan Lieber as Managing Dire...

HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are a few biotech companies you will want to know about. An oversold biotech with huge upside ...

We at White Diamond Research like shorting medical device companies with an inefficient product or products. Last year, we exposed Transenterix ( TRXC ) and Viveve Systems ( VIVE ) as each has a medical device that is fundamentally flawed. Our next medical device stock short idea is Heli...

WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, today provided an update on the NeoCart regulatory pathway based on...

WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq: HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its third quarter 2018 financial results on November 8, ...